The chemopreventive effect of mifepristone on mammary tumorigenesis is associated with an anti-invasive and anti-inflammatory gene signature

Cancer Prevention Research

Volumn 5, Issue 5, 2012, Pages 754-764

  Yuan, Hongyan ^a   Upadhyay, Geeta ^a   Lu, Jin ^a   Kopelovich, Levy ^b   Glazer, Robert I ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ADIPONECTIN; AMPHIREGULIN; AQUAPORIN 1; AQUAPORIN 3; CALCITONIN; CELL NUCLEUS RECEPTOR; CHOLINEPHOSPHOTRANSFERASE; CLAUDIN 6; COLLAGEN; COLLAGEN TYPE 9; COMPLEMENT COMPONENT C1Q; CREATINE KINASE; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CYSTEINE DIOXYGENASE; DIACYLGLYCEROL ACYLTRANSFERASE 2; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; ESTROGEN RECEPTOR ALPHA; FATTY ACID BINDING PROTEIN 4; GESTAGEN; GLUTATHIONE TRANSFERASE A4; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; KHELLIN; LECTIN; LONG CHAIN FATTY ACID COENZYME A LIGASE; MIFEPRISTONE; TRANSCRIPTION FACTOR PAX8; UNINDEXED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CARCINOGEN; HORMONE ANTAGONIST; PAIRED BOX TRANSCRIPTION FACTOR; PAX8 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; INFLAMMATION; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; ANIMAL; CARCINOMA; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; MICROARRAY ANALYSIS; PATHOLOGY; TRANSGENIC MOUSE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOGENS; CARCINOMA; CHEMOPREVENTION; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HORMONE ANTAGONISTS; INFLAMMATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MICROARRAY ANALYSIS; MIFEPRISTONE; NEOPLASM INVASIVENESS; PAIRED BOX TRANSCRIPTION FACTORS;

EID: 84866154772     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0526     Document Type: Article

References (58)

1. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr, et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995;9:2266-78.
2. Shyamala G, Yang X, Cardiff RD, Dale E. Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Natl Acad Sci U S A 2000;97:3044-9. (Pubitemid 30183252)
3. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A 2010;107:2989-94.
4. Lydon JP, Ge G, Kittrell FS, Medina D, O'Malley BW. Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res 1999;59:4276 -84.
5. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM, Lydon J. Hormone dependence in premalignant mammary progression. Cancer Res 2003;63:1067-72. (Pubitemid 36278440)
6. Lanari C, Molinolo AA, Pasqualini CD. Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice. Cancer Lett 1986;33:215-23. (Pubitemid 17194510)
7. Blank EW, Wong PY, Lakshmanaswamy R, Guzman R, Nandi S. Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats. Proc Natl Acad Sci U S A 2008;105:3527-32. (Pubitemid 351723586)
8. Kariagina A, Aupperlee MD, Haslam SZ. Progesterone receptor isoform functions in normal breast development and breast cancer. Crit Rev Eukaryot Gene Expr 2008;18:11-33. (Pubitemid 350259932)
9. Coyle YM, Xie XJ, Hardy DB, Ashfaq R, Mendelson CR. Progesterone receptor expression is a marker for early stage breast cancer: implications for progesterone receptor as a therapeutic tool and target. Cancer Lett 2007;258:253-61. (Pubitemid 350101023)
10. King TA, Gemignani ML, LiW, Giri DD, Panageas KS, Bogomolniy F, et al. Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers. Cancer Res 2004;64: 5051 - 3.
11. Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 2008;93:3295-8.
12. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A 2008;105:5774-9. (Pubitemid 351758448)
13. Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Influence ofHRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial. Hum Reprod 2004;19:741-56. (Pubitemid 38344544)
14. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 2002;95:2455-64. (Pubitemid 35424029)
15. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2002;11:1375-81. (Pubitemid 35340372)
16. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91. (Pubitemid 30062864)
17. Herrmann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, et al. [The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy]. C R Seances Acad Sci III 1982;294:933-8.
18. Klijn JG, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 2000;65:825-30.
19. El Etreby MF, Liang Y. Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. Breast Cancer Res Treat 1998;49:109-17. (Pubitemid 28279588)
20. Liang Y, Besch-Williford C, Brekken RA, Hyder SM. Progestindependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res 2007;67: 9929 - 36.
21. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1- mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006;314:1467-70. (Pubitemid 44871955)
22. Schneider MR, Michna H, Nishino Y, El Etreby MF. Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J Steroid Biochem Mol Biol 1990;37:783-7.
23. Wiehle RD, Christov K, Mehta R. Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin. Oncol Rep 2007;18:167-74.
24. Baulieu EE. Contragestion and other clinical applications ofRU486, an antiprogesterone at the receptor. Science 1989;245:1351-7.
25. El Etreby MF, Liang Y, Johnson MH, Lewis RW. Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice. Prostate 2000;42:99- 106.
26. Yin Y, Yuan H, Zeng X, Kopelovich L, Glazer RI. Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification. Cancer Res 2009;69: 687- 94.
27. Yin Y, Bai R, Russell RG, Beildeck ME, Xie Z, Kopelovich L, et al. Characterization of medroxyprogesterone and DMBA-induced multilineage mammary tumors by gene expression profiling. Mol Carcinog 2005;44:42-50. (Pubitemid 41216406)
28. Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, et al. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 2005;65:3950-7. (Pubitemid 40616378)
29. Pollock C, Yin Y, Yuan H, Zeng X, King S, Li X, et al. PPARd activation acts cooperatively with 3-phosphoinositide-dependent protein kinase- 1 to enhance mammary tumorigenesis. PLoS One 2011;6:e16215.
30. Yuan H, Upadhyay G, Yin Y, Kopelovich L, Glazer RI. Stem Cell Antigen-1 Deficiency Enhances the Chemopreventive Effect of Peroxisome Proliferator-Activated Receptor{gamma} Activation. Cancer Prev Res 2011;4:1-10.
31. IDT. [cited March 2012.] http://www.idtdna.com/Scitools/Applications/ RealTimePCR/.
32. Huang AL, Ostrowski MC, Berard D, Hager GL. Glucocorticoid regulation of the Ha-MuSV p21 gene conferred by sequences from mouse mammary tumor virus. Cell 1981;27:245-55. (Pubitemid 12200494)
33. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, et al. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 2006;13:1109-20. (Pubitemid 46212566)
34. Grigoriadis A, Mackay A, Reis-Filho JS, Steele D, Iseli C, Stevenson BJ, et al. Establishment of the epithelial-speci fic transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res 2006;8:R56.
35. Wargon V, Helguero LA, Bolado J, Rojas P, Novaro V, Molinolo A, et al. Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas. Breast Cancer Res Treat 2009;116:449-60.
36. Cui X, Lazard Z, Zhang P, Hopp TA, Lee AV. Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2. Oncogene 2003;22:6937-41. (Pubitemid 37386694)
37. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006;25:7469-81. (Pubitemid 44885746)
38. Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK, et al. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev 2000;14:650-4. (Pubitemid 30176819)
39. Atli MO, Guzeloglu A, Dinc DA. Expression of wingless type (WNT) genes and their antagonists at mRNA levels in equine endometrium during the estrous cycle and early pregnancy. Anim Reprod Sci 2011;125:94- 102.
40. Liu Y, Kodithuwakku SP, Ng PY, Chai J, Ng EH, Yeung WS, et al. Excessive ovarian stimulation up-regulates the Wnt-signaling molecule DKK1 in human endometrium and may affect implantation: an in vitro co-culture study. Hum Reprod 2010;25:479-90.
41. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-90. (Pubitemid 39472954)
42. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer Lett 2005;224:1-22. (Pubitemid 40720363)
43. Jeong JW, Lee KY, Kwak I, White LD, Hilsenbeck SG, Lydon JP, et al. Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. Endocrinology 2005;146: 3490-505. (Pubitemid 41058121)
44. Delassus GS, Cho H, Eliceiri GL. New signaling pathways from cancer progression modulators to mRNA expression of matrix metalloproteinases in breast cancer cells. J Cell Physiol 2011;226:3378- 84.
45. Tardif G, Reboul P, Pelletier JP, Martel-Pelletier J. Ten years in the life of an enzyme: the story of the human MMP-13 (collagenase-3). Mod Rheumatol 2004;14:197-204. (Pubitemid 39206663)
46. Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: an acutephase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009;66:9-26.
47. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009;27:3437-44.
48. Aldaz CM, Liao QY, LaBate M, Johnston DA. Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis 1996;17:2069-72. (Pubitemid 26325405)
49. Chandler VL, Maler BA, Yamamoto KR. DNA sequences bound specifically by glucocorticoid receptor in vitro render a heterologous promoter hormone responsive in vivo. Cell 1983;33:489-99. (Pubitemid 13062497)
50. Ballare C, Vallejo G, Vicent GP, Saragueta P, Beato M. Progesterone signaling in breast and endometrium. J Steroid Biochem Mol Biol 2006;102:2-10. (Pubitemid 44750650)
51. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293- 307.
52. Kloosterboer HJ, Deckers GH, Schoonen WG, Hanssen RG, RoseUM, Verbost PM, et al. Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids 2000;65:733- 40.
53. Michna H, Schneider MR, Nishino Y, El Etreby MF. Antitumor activity of the antiprogestins ZK 98.299 andRU38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies. Breast Cancer Res Treat 1989;14:275-88. (Pubitemid 20053757)
54. Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T, et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1996;14:2709- 12.
55. Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, Alexieva-Figusch J. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 1989;49: 2851-6. (Pubitemid 19148614)
56. Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, et al. The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 1987;74:455-61. (Pubitemid 17135278)
57. Nishino Y, Schneider MR, Michna H. Enhancement of the antitumor effi cacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384. J Cancer Res Clin Oncol 1994;120: 298- 302.
58. Thomas M, Monet JD. Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line. J Clin Endocrinol Metab 1992;75:865-70.